Pitango HealthTech MC 2022

It is a GP-led continuation fund, not a traditional primary venture fund. Pitango Venture Capital transferred existing digital-health portfolio positions from older funds into this 2022 vehicle, providing liquidity to legacy limited partners while raising fresh capital to support those companies for a longer holding period. This structure is designed for assets that need more time to mature beyond the typical ten-year venture fund life.

The fund falls under Pitango Venture Capital, which is co-managed by Managing General Partners Chemi Peres and Rami Kalish. They have led the firm together since the mid-1990s and oversee all of Pitango's fund strategies, including this dedicated health-tech continuation vehicle.

The vehicle was formed to recapitalize existing Pitango digital-health holdings, not to source new primary deals. It acquires secondary stakes from older Pitango funds, which allows the GP to concentrate follow-on capital into its highest-conviction later-stage healthcare assets while giving earlier investors a path to liquidity.

The fund holds positions in digital-health companies that were originally backed by Pitango's primary venture funds. While individual holdings are not publicly disclosed at the vehicle level, Pitango's broader health-tech track record spans medical devices, care-delivery platforms, and AI-enabled diagnostics, concentrated in Israel and the United States.

Continuation funds of this type are typically structured with a mix of rolled-over LP interests and new capital from secondary market investors or existing limited partners who choose to re-up. Whether this specific vehicle is still accepting commitments requires direct inquiry with Pitango's investor-relations team, as terms vary by fund.